BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cyprotex (COTXF.PK) Adds In Vitro Toxicology Services


8/20/2010 10:40:42 AM

London -- August 19, 2010 Cyprotex PLC (LSE:CRX), the preclinical ADME Tox services company, today announces the launch of its new in vitro toxicology service, branded as Cyprotox®. Supporting the new service is an additional 90 square metres of laboratory space at Cyprotex’s Macclesfield, UK facility housing the latest technology in multi-parametric automated fluorescent imaging and cellular analysis. This gives Cyprotex’s Macclesfield site the same in vitro toxicology capabilities as those of Apredica (Watertown, MA, USA), which Cyprotex acquired on 6 August 2010.

The new facility includes a Thermo Scientific Cellomics ArrayScan® VTI HCS Reader, which complements the four Cellomics HCS instruments used at Apredica. The ArrayScan® utilises High Content Screening (HCS) technology to determine multi-parametric indicators of toxicity. HCS is a recent breakthrough for early toxicology assessment. It has been extensively validated, and is now being adopted throughout the pharmaceutical industry.

In addition to HCS, the new facility offers many other services to assess toxicity, including:

• reactive metabolite detection

• mitochondrial toxicity;

• hERG inhibition;

• toxicological gene regulation;

• phospholipidosis;

• phototoxicity;

• haemolysis;

• genotoxicity; and

• a full spectrum of drug-drug interaction assays.

Dr Anthony Baxter, Cyprotex’s Chief Executive Officer, comments on the launch of the new toxicology facility.

“Drug toxicity, and drug-induced liver injury in particular, is a major reason for failures in clinical trials and for the withdrawal of previously approved drugs from the market. Toxicity is the most costly problem in drug development today. Identifying potential liabilities at an early stage in drug discovery decreases the likelihood of late-stage failures, and promises to produce the same magnitude of drug development efficiency improvements that preclinical ADME has provided.

“Cyprotex’s new toxicology facility complements our existing ADME business, and it aligns the capabilities of our UK facility with those of Apredica’s US facility, which Cyprotex acquired earlier this month. The combination of in vitro ADME, in vitro toxicology, and Cyprotex’s proprietary predictive modeling and proprietary CellCiphrTM technology acquired from Cellumen gives Cyprotex’s customers access to the most extensive and advanced portfolio of early ADME Tox services on the market today.”

Enquiries:

Cyprotex PLC Tel: +44 (0) 1625 505 100 Dr Anthony Baxter, Chief Executive Officer John Dootson, Chief Financial Officer Mark Warburton, Chief Operating Officer and Legal Counsel ir@cyprotex.com www.cyprotex.com

Singer Capital Markets Limited (broker to Cyprotex) Tel: +44 (0) 203 205 7500 Shaun Dobson shaun.dobson@singercm.com

Claes Spang claes.spang@singercm.com www.singerscm.com

Financial Dynamics Tel: +44 (0) 20 7831 3113 Ben Brewerton Ben Atwell Mo Noonan cyprotex@fd.com www.fd.com

Mo Noonan Senior Manager Financial Communications

Holborn Gate, 26 Southampton Buildings London, WC2A 1PB T +44 (0)20 7269 7116 F +44 (0)20 7242 8676 M +44 (0)7876 444 977 www.fd.com

A member of FTI Consulting Inc.



Read at BioSpace.com

Cyprotex
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES